Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Hologic Inc. Panther Fusion SARS-CoV-2 Assay

ASPR’s Portfolio of COVID-19 Medical Countermeasures under EUA  

BARDA is supporting the development of Hologic Inc.’s Panther Fusion SARS-CoV-2 assay, which is based on the widely-used Panther Fusion platform. This widely-used fully-automated, sample-to-answer platform can provide initial results in less than 3 hours and process 1,000 tests in 24 hours and could deliver test results in 3 hours, greatly expanding U.S. capacity to detect the virus. To learn more, see the award announcement.

Emergency Use Authorization

On March 16, 2020, FDA issued an Emergency Use Authorization (EUA) to allow Hologic Inc.’s Panther Fusion SARS-CoV-2 assay to be used to diagnose COVID-19.


  • This page last reviewed: May 21, 2020